Variations in Metformin Prescribing for Type 2 Diabetes

References

1. 1.↵
   Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854–65.

   OpenUrlCrossRefPubMedWeb of Science
2. 2.↵
   American Diabetes Association. Standards of medical care in diabetes—2015. Diabetes Care 2015;38(Suppl 1):S1–90.

   OpenUrlFREE Full Text
3. 3.↵
   Glucophage [package insert]. Princeton NJ: Bristol Myers Squibb; 2009.
4. 4.↵
   Lexicomp, Lexi-Drugs [database online]. Metformin. Hudson, Ohio: Lexi-Comp, Inc.; January 29, 2015. Available at: www.lexicomponline.com. Accessed October 3, 2015.
5. 5.↵
   Drug Facts and Comparisons. Metformin hydrochloride. Facts & Comparisons [database online]. St. Louis (MO): Wolters Kluwer Health; 2005. Available from: http://online.factsandcomparisons.com. Accessed November 20, 2014.
6. 6.↵
   1. Desai NR,
   2. Shrank WH,
   3. Fischer MA,
   4. et al

   . Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications. Am J Med 2012;125:302.e1–7.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Calabrese AT,
   2. Coley KC,
   3. DuPose SV,
   4. Swanson D,
   5. Rao RH

   . Evaluation of prescribing practices: risk of lactic acidosis with metformin therapy. Arch Intern Med 2002;162:434–7.

   OpenUrlCrossRefPubMedWeb of Science
8. 8.↵
   1. Berkowitz SA,
   2. Krumme AA,
   3. Avorn J,
   4. et al

   . Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study. JAMA Intern Med 2014;174:1955–62.

   OpenUrlPubMed
9. 9.↵
   1. Salpeter SR,
   2. Greyber E,
   3. Pasternak GA,
   4. Salpeter EE

   . Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010;(4):CD002967.
10. 10.↵
    1. Norwood DK,
    2. Chilipko AA,
    3. Amin SM,
    4. Macharia D,
    5. Still KL

    . Evaluating the potential benefits of metformin in patients with cardiovascular disease and heart failure. Consult Pharm 2013;28:579–83.

    OpenUrlPubMed
11. 11.↵
    1. Eurich DT,
    2. Weir DL,
    3. Majumdar SR,
    4. et al

    . Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail 2013;6:395–402.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Richy FF,
    2. Sabido-Espin M,
    3. Guedes S,
    4. Corvino FA,
    5. Gottwald-Hostalek U

    . Incidence of lactic acidosis in patients with type 2 diabetes with and without renal impairment treated with metformin: a retrospective cohort study. Diabetes Care 2014;37:2291–5.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Lipska KJ,
    2. Bailey CJ,
    3. Inzucchi SE

    . Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 2011;34:1431–7.

    OpenUrlFREE Full Text
14. 14.↵
    1. Maclaren R,
    2. McQueen RB,
    3. Campbell J

    . Clinical and financial impact of pharmacy services in the intensive care unit: pharmacist and prescriber perceptions. Pharmacotherapy 2013;33:401–10.

    OpenUrlPubMed
15. 15.↵
    1. Chadban S,
    2. Howell M,
    3. Twigg S,
    4. et al

    . Assessment of kidney function in type 2 diabetes. Nephrology 2010;15:S146–61.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Trinkley KE,
    2. Nikels M,
    3. Page RL II.,
    4. Joy MS

    . Automating and estimating glomerular filtration rate for dosing medications and staging chronic kidney disease. Int J Gen Med. 2014;7:211–8.

    OpenUrlPubMed